| Inhibition of proteasome deubiquitinating activity as a new cancer therapy P D'arcy, S Brnjic, MH Olofsson, M Fryknäs, K Lindsten, M De Cesare, ... Nature medicine 17 (12), 1636-1640, 2011 | 541 | 2011 |
| Deubiquitinase inhibition as a cancer therapeutic strategy P D'Arcy, X Wang, S Linder Pharmacology & therapeutics 147, 32-54, 2015 | 337 | 2015 |
| A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance Z Tian, P D’Arcy, X Wang, A Ray, YT Tai, Y Hu, RD Carrasco, ... Blood, The Journal of the American Society of Hematology 123 (5), 706-716, 2014 | 330 | 2014 |
| Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments X Zhang, M Fryknäs, E Hernlund, W Fayad, A De Milito, MH Olofsson, ... Nature communications 5 (1), 3295, 2014 | 243 | 2014 |
| Cancer/Testis Antigen Expression in Human Mesenchymal Stem Cells: Down-regulation of SSX Impairs Cell Migration and Matrix Metalloproteinase 2 Expression G Cronwright, K Le Blanc, C Götherström, P Darcy, M Ehnman, ... Cancer research 65 (6), 2207-2215, 2005 | 196 | 2005 |
| The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells X Wang, M Mazurkiewicz, EK Hillert, MH Olofsson, S Pierrou, P Hillertz, ... Scientific reports 6 (1), 26979, 2016 | 153 | 2016 |
| Proteasome deubiquitinases as novel targets for cancer therapy P D’Arcy, S Linder The international journal of biochemistry & cell biology 44 (11), 1729-1738, 2012 | 153 | 2012 |
| Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug X Zhang, K Selvaraju, AA Saei, P D'Arcy, RA Zubarev, ESJ Arnér, ... Biochimie 162, 46-54, 2019 | 138 | 2019 |
| Synthesis and Evaluation of Derivatives of the Proteasome Deubiquitinase Inhibitor b‐AP 15 X Wang, P D'Arcy, TR Caulfield, A Paulus, K Chitta, C Mohanty, J Gullbo, ... Chemical biology & drug design 86 (5), 1036-1048, 2015 | 102 | 2015 |
| Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress S Brnjic, M Mazurkiewicz, M Fryknäs, C Sun, X Zhang, R Larsson, ... Antioxidants & redox signaling 21 (17), 2271-2285, 2014 | 88 | 2014 |
| Proteasome-associated deubiquitinases and cancer A Mofers, P Pellegrini, S Linder, P D’Arcy Cancer and Metastasis Reviews 36, 635-653, 2017 | 85 | 2017 |
| The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death X Wang, W Stafford, M Mazurkiewicz, M Fryknäs, S Brjnic, X Zhang, ... Molecular pharmacology 85 (6), 932-945, 2014 | 78 | 2014 |
| Doxorubicin sensitizes human tumor cells to NK cell‐and T‐cell‐mediated killing by augmented TRAIL receptor signaling E Wennerberg, D Sarhan, M Carlsten, VO Kaminskyy, P D'Arcy, ... International journal of cancer 133 (7), 1643-1652, 2013 | 71 | 2013 |
| Targeting mitochondrial function to treat quiescent tumor cells in solid tumors X Zhang, A De Milito, MH Olofsson, J Gullbo, P D’Arcy, S Linder International journal of molecular sciences 16 (11), 27313-27326, 2015 | 69 | 2015 |
| Deubiquitinating enzymes in coronaviruses and possible therapeutic opportunities for COVID-19 V Clemente, P D’arcy, M Bazzaro International Journal of Molecular Sciences 21 (10), 3492, 2020 | 67 | 2020 |
| Iron chelators target both proliferating and quiescent cancer cells M Fryknäs, X Zhang, U Bremberg, W Senkowski, MH Olofsson, P Brandt, ... Scientific reports 6 (1), 38343, 2016 | 65 | 2016 |
| Molecular pathways: translational potential of deubiquitinases as drug targets P D'Arcy, S Linder Clinical Cancer Research 20 (15), 3908-3914, 2014 | 60 | 2014 |
| Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties W Fayad, L Rickardson, C Haglund, MH Olofsson, P D’Arcy, R Larsson, ... Chemical biology & drug design 78 (4), 547-557, 2011 | 58 | 2011 |
| Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells P D’Arcy, W Maruwge, B Wolahan, L Ma, B Brodin PloS one 9 (4), e95136, 2014 | 49 | 2014 |
| Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors? K Selvaraju, M Mazurkiewicz, X Wang, J Gullbo, S Linder, P D’Arcy Drug resistance updates 21, 20-29, 2015 | 47 | 2015 |
